TriangleInobrodib (NCT07096778)
Inobrodib trial for Multiple Myeloma Refractory (NCT07096778). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with relapsed or refractory multiple myeloma resistant to a proteasome inhibitor, an anti-CD38 antibody and pomalidomide. Previous treatment with an approved bispecific T-cell engager is required.
The idea: add oral inobrodib to pomalidomide and dexamethasone. Inobrodib blocks p300/CBP bromodomains, disrupting gene regulation that can support tumor growth. It is taken twice daily, four days on and three days off. Researchers measure responses and side effects without a comparison group. Previous p300/CBP-inhibitor treatment excludes participation.
This phase 2 study plans 100 patients. CellCentric sponsors twenty-one recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.